Someone’s Selling Pfizer Inc. (PFE) Shares, Should You?
Now, according to many traders, hedge funds are seen as delayed, outdated investment tools of an era lost to time.
Posts Tagged ‘NYSE:NVS’
Novartis AG (ADR) (NVS), Amgen, Inc. (AMGN): Incyte Corporation (INCY) Jumps on Jakafi Results
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Biogen Idec Inc. (BIIB), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Novartis AG (ADR) (NVS): Companies Leading the Fight Against Multiple Sclerosis
It's a disease that doesn't often find itself in the spotlight, but multiple sclerosis is quickly becoming an ailment that drugmakers are focusing their efforts on to make a quality...
Incyte Corporation (INCY), BioMarin Pharmaceutical Inc. (BMRN): Two Biotech Stocks That Could Be on Novartis AG (ADR) (NVS)’s Buyout Radar
The buyout drama surrounding cancer drug maker Onyx Pharmaceuticals, Inc.
Merck & Co., Inc. (MRK), Novartis AG (ADR) (NVS): One Hidden Pharmaceutical Technology for Your Portfolio
Pharmaceutical companies are always looking for competitive advantages.
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS): This Company’s Debt Might Be a Concern
GlaxoSmithKline plc (ADR) (NYSE:GSK) has been accused of making illegal payments to Chinese doctors and government officials by siphoning them through travel agencies.
Roche Holding Ltd. (ADR) (RHHBY), Novartis AG (ADR) (NVS): Should You Keep an Eye on These Eye Treatment Biotechs?
Investors might want to keep their eyes on the eye care industry, as the battle for eye treatments heats up across the biotech sector.
Theravance Inc (THRX), Novartis AG (ADR) (NVS): Respiratory Drug Maker About to Take Off
Chronic obstructive pulmonary disease (COPD) is America’s third leading cause of death.
Eli Lilly & Co. (LLY), Novartis AG (ADR) (NVS): Is This Company Getting Ahead of Itself?
The biotechnology industry is one of the riskiest places to put your money. However, when companies get everything right, the fortunes made there are usually massive.
Celgene Corporation (CELG), Novartis AG (ADR) (NVS): Momenta Pharmaceuticals, Inc. (MNTA) Earnings Remind Investors of Growing Pains
The investing waters can get pretty choppy from time to time with a developmental stage company. A look at the five-year chart of Momenta Pharmaceuticals, Inc.
3 Things You Need to Know From Astex Pharmaceuticals, Inc. (ASTX)’s Q2 Earnings
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Amgen, Inc. (AMGN), Baxter International Inc. (BAX): Can the FDA Make Up Its Mind Already?
It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration...
Incyte Corporation (INCY) Earnings Cruise on Jakafi Growth
Budding biotech company Incyte Corporation (NASDAQ:INCY), which specializes in developing novel JAK inhibitors, released solid second-quarter earnings on Wednesday.
Biogen Idec Inc (BIIB), Pfizer Inc. (PFE): Out With the Old, In With the New in Treating MS
Hidden beneath all the numbers and metrics in Biogen Idec Inc (NASDAQ:BIIB)'s recent earnings report is a key confirmation of a shifting market in the treatment of multiple sclerosis...
Theravance Inc (THRX), GlaxoSmithKline plc (ADR) (GSK): Which of These COPD Treatments Will Come Out on Top?
To most people, cigarettes are often associated with lung cancer.
Alexion Pharmaceuticals, Inc. (ALXN): Extremely Expensive Drugs for Extremely Rare Diseases
The biotech industry is known for fast paced acquisitions and rapid market consolidation.
Momenta Pharmaceuticals, Inc. (MNTA) Latest to Take Advantage of Teva Pharmaceutical Industries Ltd (ADR) (TEVA)’s Patent Woes
The United States Court of Appeals is making this one miserable summer for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Pfizer Inc. (PFE): As Healthcare Demand Rises, So Will This Company’s Profits
The aging population as well as the higher number of people who will receive benefits under new healthcare laws should combine to produce rising profits for a variety of companies...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Will This Biotech Bidding War Lead You to Larger Gains?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Alkermes Plc (ALKS), Quest Diagnostics Inc (DGX): This Week in Biotech
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
A Look at Novartis AG (ADR) (NVS)’ Second Quarter
The story of the second quarter for Novartis AG (ADR) (NYSE:NVS) offered mixed results for investors. The company's net sales were up 1%, and EPS was down 6% year over year.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Which Pharmaceutical Giant Is the Best Investment?
Amid sluggish sales growth, the Pharmaceutical Industry giants are struggling with declining revenues and profits.
Merck & Co., Inc. (MRK): This Pharmaceutical Company Is Poised for Wellness
Sustainability and a strong pipeline are the two tests that best evaluate a pharmaceutical company. Merck & Co., Inc. (NYSE:MRK) scores high on both counts.
GlaxoSmithKline plc (ADR) (GSK), Theravance Inc (THRX), Pfizer Inc. (PFE): 3 Potential Game Changers for COPD
Over 13 million Americans have it. More than 120,000 of them die every year.
Jazz Pharmaceuticals plc – Ordinary Shares (JAZZ), Novartis AG (ADR) (NVS): Don’t Let Your Attention Defect
Ineffective drugs being sold for billions in global sales.
The Boeing Company (BA), Lockheed Martin Corporation (LMT) – Pentagon Watch: Where Did Your Tax Dollars Go This Week?
The U.S. military has a reputation as a somewhat secretive organization. But in one respect at least, the Pentagon ranks among our most transparent government agencies.
Wells Fargo & Co (WFC), Baxter International Inc. (BAX): Obamacare-Inspired Investment Opportunities
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
AstraZeneca plc (ADR) (AZN), Sanofi SA (ADR) (SNY): Don’t Ignore These European Healthcare Stocks
Healthcare stocks have rallied over the past couple years, and for good reason.
Sanofi SA (ADR) (SNY), Novo Nordisk A/S (ADR) (NVO), Johnson & Johnson (JNJ): Can Investors Bet on These 3 Pharma Companies?
It is expected that the death rate from diabetes will top 50% in the next ten years, which will make it a leading cause of death worldwide.
Aegerion Pharmaceuticals, Inc. (AEGR), Arena Pharmaceuticals, Inc. (ARNA): Investment Opportunities in Drug Launches
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
Johnson & Johnson (JNJ): New Drugs and Better Manufacturing Make This Stock a Buy
Johnson & Johnson (NYSE:JNJ) stands alone as a leader across the major health-care industries.
Johnson & Johnson (JNJ): Why Might This Play Shake Up the Cancer-Drug Industry?
Medical firm Johnson & Johnson (NYSE:JNJ) recently announced a private-company acquisition that could have major implications for one of the markets in which it operates.
Hedge Funds Are Betting On Pfizer Inc. (PFE)
Pfizer Inc. (NYSE:PFE) was in 81 hedge funds' portfolio at the end of the first quarter of 2013. PFE shareholders have witnessed an increase in hedge fund interest recently.
Idenix Pharmaceuticals Inc (IDIX), GenMark Diagnostics, Inc (GNMK): Horrendous Health-Care Stocks This Week
Shares of small biotech Idenix Pharmaceuticals Inc (NASDAQ:IDIX) took a 32% nosedive this week, following unwelcome news from the U.S. Food and Drug Administration.
Myriad Genetics, Inc. (MYGN): Big Pharma’s Intellectual Property Blues
It’s not easy being a biotech company.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): These 2 Healthcare Stocks Could Win Big With FDA’s New ‘Breakthrough’ Status
The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for...
Biogen Idec Inc. (BIIB), Sanofi SA (ADR) (SNY): A Must Have Pharma Stock
After a year-long dream run, Biogen Idec Inc. (NASDAQ:BIIB) lost 5.25% in the week ended Friday, June 7.
Questcor Pharmaceuticals Inc (QCOR), Avanir Pharmaceuticals, Inc. (AVNR): 3 Humongous Healthcare Stocks This Past Week
Investors in a handful of health-care stocks are probably all smiles this week. Several stocks saw nice double-digit gains over the past five days.
AstraZeneca plc (ADR) (AZN), GlaxoSmithKline plc (ADR) (GSK): A Big Pharma Company With a Juicy Dividend Yield and Low Valuation
Recently, AstraZeneca plc (ADR) (NYSE:AZN) announced that it has agreed to acquire Pearl Therapeutics, the respiratory drug manufacturer, in a transaction worth around $1.15 billion...
AstraZeneca plc (ADR) (AZN), Novartis AG (ADR) (NVS): 5 Biotech Giants with Lucrative Dividend Yields
Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance.
Why The Pfizer Inc. (PFE)-Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Settlement Affects the Whole Industy
Generic-drug makers are always on the hunt for the next branded drug to take down.
Valeant Pharmaceuticals Intl Inc (VRX) Biting More Than it Can Chew
While the debate goes on whether increasing output by acquiring new businesses through mergers, acquisitions and takeovers is the right way forward, the biopharmaceutical industry...
Valeant Pharmaceuticals Intl Inc (VRX): This Company is Set for Newer Heights in the Eye-Care Sector
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been on an acquisition spree. Its latest purchase is Bausch + Lomb in an all-cash deal worth $8.7 billion.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Juicy Dividends From the Three Pharmaceutical Giants
Merck & Co., Inc. (NYSE:MRK) has been trying to generate more value for its shareholders via its share buyback program.
Why Questcor Pharmaceuticals Inc (QCOR) Shares Exploded Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Questcor Pharmaceuticals, Inc. (QCOR) Buys Potential Rival Drug
Why try to beat 'em if you can just buy 'em? That's the approach that Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) is taking.
Celgene Corporation (CELG)’s Abraxane: A Therapy for Advanced Pancreatic Cancer?
Celgene Corporation (NASDAQ:CELG)’s Abraxane is primarily used to treat breast and lung cancer.
Merck & Co., Inc. (MRK), Clovis Oncology Inc (CLVS): All About ASCO – 2013 Highlights
Every week at The Motley Fool we reflect on the top stories in the biotech sector in a wrap-up column.
